Adlai Nortye - ADR opened lower at $10.62, compared with its previous close of $10.85. In the last trading session, the stock traded between $10.22 and $10.79. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Adlai Nortye - ADR is now worth
$ 70.25
Resulting in a loss of
$ 29.75 (29.75%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.31 (-2.88%)
Day High
$10.79
Day Low
$10.22
Day Open
$10.62
Prev Close
$10.85
Volume
1,14,118
1W Return
9.54%
1M Return
-25.46%
3M Return
-19.28%
6M Return
-18.69%
1Y Return
550.49%
Fundamentals
Market Cap ($ Mn)
768
PE Ratio
-
PB Ratio
4.53
PEG Ratio
-
ROE
-
ROCE
-379.73%
EPS (TTM)
-
Investment Returns
1 Week
9.54%
1 Month
-25.46%
3 Months
-19.28%
6 Months
-18.69%
9 Months
13.43%
Financials
Quarterly
All values in $ Mn
0.0
Mar 22
0.0
Jun 22
0.0
Mar 23
0.0
Jun 23
Updates
15Oct
Adlai Nortye signs cetuximab supply deals with Lilly and Merck
Adlai Nortye signs supply agreements with Eli Lilly and Merck KGaA. Cetuximab provided at no cost for US, Australia, and China sites. Supports Phase I trial of AN4035 ADC for RAS-addicted solid tumors.
28 days ago
14Aug
Adlai Nortye H1FY26 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M
Adlai Nortye Ltd. (NASDAQ: ANL) reported H1FY26 EPS of $(0.04), a 78.95% improvement from $(0.19) YoY. Revenue reached $13.056 million from licensing deals. Cash reserves grew to $231.9 million following $290 million in equity raises.
3mo ago
3Aug
Adlai Nortye clears AN4035 for Phase I trial in Australia, dosing starts H2 2026
Adlai Nortye Ltd. secured Australian regulatory clearance for its Phase I trial of AN4035, a first-in-class pan-RAS(ON) ADC targeting CEACAM5-enriched solid tumors. The trial will evaluate safety and efficacy as monotherapy and with cetuximab, with dosing starting in H2 2026. IND applications are also in process with the U.S. FDA and China NMPA.
3mo ago
16Jul
Adlai Nortye doses first patient in AN9025 weekly arm
Adlai Nortye has dosed the first patient in the intermittent weekly dosing arm of its Phase 1 trial for AN9025, a Pan-RAS(ON) inhibitor. The trial aims to widen the therapeutic window for advanced solid tumors.
3mo ago
13Jul
Adlai Nortye expands Scientific Advisory Board with oncologists
Adlai Nortye Ltd. has appointed Dr. David S. Hong and Dr. Piro Lito to its Scientific Advisory Board to enhance its R&D strategy and clinical development. The new members will guide the company's RAS inhibitor programs, including AN9025 and AN4035, and its immuno-oncology candidate AN8025. Adlai Nortye's pipeline focuses on precision RAS pathway targeted therapies and next-generation PD-1/L1 pathway modulating immunotherapies.
4mo ago
22Jun
Cantor Fitzgerald initiates coverage on Adlai Nortye with Overweight rating
Cantor Fitzgerald analyst Li Watsek has initiated coverage on Adlai Nortye with an Overweight rating. The rating indicates a bullish stance on the company's stock performance.
